Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells

Hiromi Sato, Sana Siddig, Miaki Uzu, Sayumi Suzuki, Yuki Nomura, Tatsuro Kashiba, Keisuke Gushimiyagi, Yuko Sekine, Tomoya Uehara, Yasushi Arano, Katsunori Yamaura, Koichi Ueno

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Intrinsic drug resistance occurs in many renal carcinomas and is associated with increased expression of multidrug resistant proteins, which inhibits intracellular drug accumulation. Multidrug resistant protein 1, also known as P-glycoprotein, is a membrane drug efflux pump belonging to the ATP-binding cassette (ABC) transporter superfamily. ABC Sub-family B Member 2 (ABCG2) is widely distributed and is involved in the multidrug resistant phenotype. Sunitinib is a tyrosine kinase inhibitor used to treat kidney cancer that disrupts signaling pathways responsible for abnormal cancer cell proliferation and tumor angiogenesis. Multiple drug resistance is important in tyrosine kinase inhibitor-induced resistance. We hypothesized that inhibition of multidrug resistant transporters by elacridar (dual inhibitor of P-glycoprotein and ABCG 2) might overcome sunitinib resistance in experimental renal cell carcinoma. Human renal carcinoma cell lines 786-O, ACHN, and Caki-1 were treated with sunitinib or elacridar alone, or in combination. We showed that elacridar significantly enhanced sunitinib cytotoxicity in 786-O cells. P-glycoprotein activity, confirmed by P-glycoprotein function assay, was found to be inhibited by elacridar. ABCG2 expression was low in all renal carcinoma cell lines, and was suppressed only by combination treatment in 786-O cells. ABCG2 function was inhibited by sunitinib alone or combination with elacridar but not elacridar alone. These findings suggest that sunitinib resistance involves multidrug resistance transporters, and in combination with elacridar, can be reversed in renal carcinoma cells by P-glycoprotein inhibition.

Original languageEnglish
Pages (from-to)258-266
Number of pages9
JournalEuropean Journal of Pharmacology
Volume746
DOIs
Publication statusPublished - 2015 Jan 5
Externally publishedYes

Fingerprint

Multiple Drug Resistance
Renal Cell Carcinoma
P-Glycoprotein
Carcinoma
Kidney
Protein-Tyrosine Kinases
Cell Line
ATP-Binding Cassette Transporters
Kidney Neoplasms
Elacridar
sunitinib
Drug Resistance
Pharmaceutical Preparations
Neoplasms
Proteins
Cell Proliferation
Phenotype
Membranes

Keywords

  • ABCG2
  • Drug resistance
  • P-glycoprotein
  • Renal cell carcinoma
  • Sunitinib

ASJC Scopus subject areas

  • Pharmacology
  • Medicine(all)

Cite this

Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells. / Sato, Hiromi; Siddig, Sana; Uzu, Miaki; Suzuki, Sayumi; Nomura, Yuki; Kashiba, Tatsuro; Gushimiyagi, Keisuke; Sekine, Yuko; Uehara, Tomoya; Arano, Yasushi; Yamaura, Katsunori; Ueno, Koichi.

In: European Journal of Pharmacology, Vol. 746, 05.01.2015, p. 258-266.

Research output: Contribution to journalArticle

Sato, H, Siddig, S, Uzu, M, Suzuki, S, Nomura, Y, Kashiba, T, Gushimiyagi, K, Sekine, Y, Uehara, T, Arano, Y, Yamaura, K & Ueno, K 2015, 'Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells', European Journal of Pharmacology, vol. 746, pp. 258-266. https://doi.org/10.1016/j.ejphar.2014.11.021
Sato, Hiromi ; Siddig, Sana ; Uzu, Miaki ; Suzuki, Sayumi ; Nomura, Yuki ; Kashiba, Tatsuro ; Gushimiyagi, Keisuke ; Sekine, Yuko ; Uehara, Tomoya ; Arano, Yasushi ; Yamaura, Katsunori ; Ueno, Koichi. / Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells. In: European Journal of Pharmacology. 2015 ; Vol. 746. pp. 258-266.
@article{525f98eae72b47e78078e81a766e1850,
title = "Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells",
abstract = "Intrinsic drug resistance occurs in many renal carcinomas and is associated with increased expression of multidrug resistant proteins, which inhibits intracellular drug accumulation. Multidrug resistant protein 1, also known as P-glycoprotein, is a membrane drug efflux pump belonging to the ATP-binding cassette (ABC) transporter superfamily. ABC Sub-family B Member 2 (ABCG2) is widely distributed and is involved in the multidrug resistant phenotype. Sunitinib is a tyrosine kinase inhibitor used to treat kidney cancer that disrupts signaling pathways responsible for abnormal cancer cell proliferation and tumor angiogenesis. Multiple drug resistance is important in tyrosine kinase inhibitor-induced resistance. We hypothesized that inhibition of multidrug resistant transporters by elacridar (dual inhibitor of P-glycoprotein and ABCG 2) might overcome sunitinib resistance in experimental renal cell carcinoma. Human renal carcinoma cell lines 786-O, ACHN, and Caki-1 were treated with sunitinib or elacridar alone, or in combination. We showed that elacridar significantly enhanced sunitinib cytotoxicity in 786-O cells. P-glycoprotein activity, confirmed by P-glycoprotein function assay, was found to be inhibited by elacridar. ABCG2 expression was low in all renal carcinoma cell lines, and was suppressed only by combination treatment in 786-O cells. ABCG2 function was inhibited by sunitinib alone or combination with elacridar but not elacridar alone. These findings suggest that sunitinib resistance involves multidrug resistance transporters, and in combination with elacridar, can be reversed in renal carcinoma cells by P-glycoprotein inhibition.",
keywords = "ABCG2, Drug resistance, P-glycoprotein, Renal cell carcinoma, Sunitinib",
author = "Hiromi Sato and Sana Siddig and Miaki Uzu and Sayumi Suzuki and Yuki Nomura and Tatsuro Kashiba and Keisuke Gushimiyagi and Yuko Sekine and Tomoya Uehara and Yasushi Arano and Katsunori Yamaura and Koichi Ueno",
year = "2015",
month = "1",
day = "5",
doi = "10.1016/j.ejphar.2014.11.021",
language = "English",
volume = "746",
pages = "258--266",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",

}

TY - JOUR

T1 - Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells

AU - Sato, Hiromi

AU - Siddig, Sana

AU - Uzu, Miaki

AU - Suzuki, Sayumi

AU - Nomura, Yuki

AU - Kashiba, Tatsuro

AU - Gushimiyagi, Keisuke

AU - Sekine, Yuko

AU - Uehara, Tomoya

AU - Arano, Yasushi

AU - Yamaura, Katsunori

AU - Ueno, Koichi

PY - 2015/1/5

Y1 - 2015/1/5

N2 - Intrinsic drug resistance occurs in many renal carcinomas and is associated with increased expression of multidrug resistant proteins, which inhibits intracellular drug accumulation. Multidrug resistant protein 1, also known as P-glycoprotein, is a membrane drug efflux pump belonging to the ATP-binding cassette (ABC) transporter superfamily. ABC Sub-family B Member 2 (ABCG2) is widely distributed and is involved in the multidrug resistant phenotype. Sunitinib is a tyrosine kinase inhibitor used to treat kidney cancer that disrupts signaling pathways responsible for abnormal cancer cell proliferation and tumor angiogenesis. Multiple drug resistance is important in tyrosine kinase inhibitor-induced resistance. We hypothesized that inhibition of multidrug resistant transporters by elacridar (dual inhibitor of P-glycoprotein and ABCG 2) might overcome sunitinib resistance in experimental renal cell carcinoma. Human renal carcinoma cell lines 786-O, ACHN, and Caki-1 were treated with sunitinib or elacridar alone, or in combination. We showed that elacridar significantly enhanced sunitinib cytotoxicity in 786-O cells. P-glycoprotein activity, confirmed by P-glycoprotein function assay, was found to be inhibited by elacridar. ABCG2 expression was low in all renal carcinoma cell lines, and was suppressed only by combination treatment in 786-O cells. ABCG2 function was inhibited by sunitinib alone or combination with elacridar but not elacridar alone. These findings suggest that sunitinib resistance involves multidrug resistance transporters, and in combination with elacridar, can be reversed in renal carcinoma cells by P-glycoprotein inhibition.

AB - Intrinsic drug resistance occurs in many renal carcinomas and is associated with increased expression of multidrug resistant proteins, which inhibits intracellular drug accumulation. Multidrug resistant protein 1, also known as P-glycoprotein, is a membrane drug efflux pump belonging to the ATP-binding cassette (ABC) transporter superfamily. ABC Sub-family B Member 2 (ABCG2) is widely distributed and is involved in the multidrug resistant phenotype. Sunitinib is a tyrosine kinase inhibitor used to treat kidney cancer that disrupts signaling pathways responsible for abnormal cancer cell proliferation and tumor angiogenesis. Multiple drug resistance is important in tyrosine kinase inhibitor-induced resistance. We hypothesized that inhibition of multidrug resistant transporters by elacridar (dual inhibitor of P-glycoprotein and ABCG 2) might overcome sunitinib resistance in experimental renal cell carcinoma. Human renal carcinoma cell lines 786-O, ACHN, and Caki-1 were treated with sunitinib or elacridar alone, or in combination. We showed that elacridar significantly enhanced sunitinib cytotoxicity in 786-O cells. P-glycoprotein activity, confirmed by P-glycoprotein function assay, was found to be inhibited by elacridar. ABCG2 expression was low in all renal carcinoma cell lines, and was suppressed only by combination treatment in 786-O cells. ABCG2 function was inhibited by sunitinib alone or combination with elacridar but not elacridar alone. These findings suggest that sunitinib resistance involves multidrug resistance transporters, and in combination with elacridar, can be reversed in renal carcinoma cells by P-glycoprotein inhibition.

KW - ABCG2

KW - Drug resistance

KW - P-glycoprotein

KW - Renal cell carcinoma

KW - Sunitinib

UR - http://www.scopus.com/inward/record.url?scp=84916897706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84916897706&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2014.11.021

DO - 10.1016/j.ejphar.2014.11.021

M3 - Article

VL - 746

SP - 258

EP - 266

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

ER -